Literature DB >> 9339704

Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient.

N De Stefano1, P M Matthews, S Narayanan, G S Francis, J P Antel, D L Arnold.   

Abstract

In a 6-year longitudinal study of a patient with relapsing progressive multiple sclerosis (MS), we used proton magnetic resonance spectroscopy to assess N-acetylaspartate (NAA) from a large central brain volume to evaluate the relationship between this marker of neuronal integrity and clinical disability. During the follow-up period, there was one major relapse and its subsequent partial remission. Changes in the brain NAA to creatine ratio correlated strongly with clinical disability (Spearman rank coefficient = -0.73, p < 0.001). We interpret this as evidence that axonal dysfunction or loss contributes to functional impairment of patients with MS. Because the NAA signal in the large volume of interest originated predominantly from white matter that appeared normal on conventional MRI, these results also suggest that some degree of axonal dysfunction may be widespread in acute, severe relapses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9339704     DOI: 10.1212/wnl.49.4.1138

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

1.  Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis.

Authors:  D B McGavern; P D Murray; C Rivera-Quiñones; J D Schmelzer; P A Low; M Rodriguez
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

Review 2.  Magnetic resonance spectroscopy in vivo: applications in neurological disorders.

Authors:  D L Arnold; N De Stefano
Journal:  Ital J Neurol Sci       Date:  1997-12

3.  Whole-brain N-acetylaspartate concentration: correlation with T2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis.

Authors:  Fabrice Bonneville; David M Moriarty; Belinda S Y Li; James S Babb; Robert I Grossman; Oded Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

4.  Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis.

Authors:  M Filippi; C Tortorella; M Rovaris; M Bozzali; F Possa; M P Sormani; G Iannucci; G Comi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

5.  ¹H- and ¹³C-NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimer's disease.

Authors:  A Doert; U Pilatus; F Zanella; W E Müller; G P Eckert
Journal:  J Neural Transm (Vienna)       Date:  2015-03-06       Impact factor: 3.575

6.  Quantitation of spinal cord demyelination, remyelination, atrophy, and axonal loss in a model of progressive neurologic injury.

Authors:  D B McGavern; P D Murray; M Rodriguez
Journal:  J Neurosci Res       Date:  1999-11-15       Impact factor: 4.164

7.  Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study.

Authors:  I Mader; W Roser; L Kappos; G Hagberg; J Seelig; E W Radue; W Steinbrich
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

Review 8.  Proton magnetic resonance spectroscopy in brain white matter disorders.

Authors:  N De Stefano; A Federico; D L Arnold
Journal:  Ital J Neurol Sci       Date:  1997-12

Review 9.  Axonal injury in multiple sclerosis.

Authors:  Kottil W Rammohan
Journal:  Curr Neurol Neurosci Rep       Date:  2003-05       Impact factor: 5.081

10.  Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis.

Authors:  Niamh Cawley; Bhavana S Solanky; Nils Muhlert; Carmen Tur; Richard A E Edden; Claudia A M Wheeler-Kingshott; David H Miller; Alan J Thompson; Olga Ciccarelli
Journal:  Brain       Date:  2015-09       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.